Production of Inhalation Phage Powders Using Spray Freeze Drying and Spray Drying Techniques for Treatment of Respiratory Infections

Pharmaceutical Research

Volumn 33, Issue 6, 2016, Pages 1486-1496

  Leung, Sharon S Y ^a   Parumasivam, Thaigarajan ^a   Gao, Fiona G ^a   Carrigy, Nicholas B ^b   Vehring, Reinhard ^b   Finlay, Warren H ^b   Morales, Sandra ^c   Britton, Warwick J ^d   Kutter, Elizabeth ^e   Chan, Hak Kim ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF ALBERTA   (Canada)

^c AmpliPhi Biosciences AU   (Australia)

^d UNIVERSITY OF SYDNEY   (Australia)

^e EVERGREEN STATE COLLEGE   (United States)

Author keywords

aerosols; antibiotic resistant bacteria; phage therapy; pulmonary infections

Indexed keywords

ANTIBIOTIC AGENT; LEUCINE; MANNITOL; RESPIRATORY TRACT AGENT; TREHALOSE; AEROSOL; POWDER;

AEROSOL; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL VIABILITY; CONTROLLED STUDY; CRYSTALLIZATION; DIFFERENTIAL SCANNING CALORIMETRY; DILUTION; DISPERSION; DRUG FORMULATION; DRUG STABILITY; DRY POWDER; FREEZE DRYING; GLASS TRANSITION TEMPERATURE; HUMIDITY; IN VITRO STUDY; INTERMETHOD COMPARISON; IONIC STRENGTH; MEASUREMENT ACCURACY; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS PHAGE; PSEUDOMONAS PHAGE PEV2; RESPIRATORY TRACT INFECTION; SCANNING ELECTRON MICROSCOPY; SPRAY DRYING; SPRAY FREEZE DRYING; SURFACE AREA; THERMOGRAVIMETRY; ULTRASOUND; X RAY DIFFRACTION; CHEMISTRY; INHALATIONAL DRUG ADMINISTRATION; LUNG; MICROBIAL VIABILITY; MICROBIOLOGY; NEBULIZER; PATHOGENICITY; PHAGE THERAPY; PODOVIRIDAE; POWDER; PROCEDURES; PSEUDOMONAS; PSEUDOMONAS INFECTIONS; RESPIRATORY TRACT INFECTIONS; VIROLOGY;

ADMINISTRATION, INHALATION; AEROSOLS; FREEZE DRYING; LEUCINE; LUNG; MANNITOL; MICROBIAL VIABILITY; NEBULIZERS AND VAPORIZERS; PHAGE THERAPY; PODOVIRIDAE; POWDERS; PSEUDOMONAS; PSEUDOMONAS INFECTIONS; RESPIRATORY TRACT INFECTIONS; TREHALOSE; ULTRASONICS;

EID: 84959369508     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-016-1892-6     Document Type: Article

References (58)

1. Williams BG, Gouws E, Boschi-Pinto C, Bryce J, Dye C. Estimates of world-wide distribution of child deaths from acute respiratory infections. Lancet Infect Dis. 2002;2(1):25–32.
2. In: Foundation TAL, editor. The Australian Lung Foundation’s case statement: respiratory infectious disease burden in Australia. 2007.
3. Govan JRW, Deretic V. Microbial pathogenesis in cystic fibrosis: mucoid Pseudomonas aeruginosa and Burkholderia cepacia. Microbiol Rev. 1996;60(3):539–74.
4. Boucher HW, Talbot GH, Bradley JS, Edwards Jr JE, Gilbert D, Rice LB, et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis. 2009;48(1):1–12.
5. Li J, Nation RL, Turnidge JD, Milne RW, Coulthard K, Rayner CR, et al. Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. Lancet Infect Dis. 2006;6(9):589–601.
6. Chmiel JF, Aksamit TR, Chotirmall SH, Dasenbrook EC, Elborn JS, LiPuma JJ, et al. Antibiotic management of lung infections in cystic fibrosis. I. The microbiome, methicillin-resistant Staphylococcus aureus, gram-negative bacteria, and multiple infections. Ann Am Thorac Soc. 2014;11(7):1120–9.
7. Hoiby N. Recent advances in the treatment of Pseudomonas aeruginosa infections in cystic fibrosis. Bmc Med. 2011;9:32.
8. Nordmann P, Naas T, Fortineau N, Poirel L. Superbugs in the coming new decade; multidrug resistance and prospects for treatment of Staphylococcus aureus, Enterococcus spp. and Pseudomonas aeruginosa in 2010. Curr Opin Microbiol. 2007;10(5):436–40.
9. Hoe S, Semler DD, Goudie AD, Lynch KH, Matinkhoo S, Finlay WH, et al. Respirable bacteriophages for the treatment of bacterial lung infections. J Aerosol Med Pulm Drug Deliv. 2013;26(6):317–35.
10. Sulakvelidze A, Alavidze Z, Morris JG. Bacteriophage therapy. Antimicrob Agents Chemother. 2001;45(3):649–59.
11. Kutter E, De Vos D, Gvasalia G, Alavidze Z, Gogokhia L, Kuhl S, et al. Phage therapy in clinical practice: treatment of human infections. Curr Pharm Biotechnol. 2010;11(1):69–86.
12. Kutateladze M, Adamia R. Phage therapy experience at the Eliava Institute. Med Mal Infect. 2008;38(8):426–30.
13. Debarbieux L, Leduc D, Maura D, Morello E, Criscuolo A, Grossi O, et al. Bacteriophages can treat and prevent Pseudomonas aeruginosa lung infections. J Infect Dis. 2010;201(7):1096–104.
14. Essoh C, Blouin Y, Loukou G, Cablanmian A, Lathro S, Kutter E, et al. The susceptibility of Pseudomonas aeruginosa strains from cystic fibrosis patients to bacteriophages. Plos One. 2013;8(4).
15. Larche J, Pouillot F, Essoh C, Libisch B, Straut M, Lee JC, et al. Rapid identification of international multidrug-resistant Pseudomonas aeruginosa clones by multiple-locus variable number of tandem repeats analysis and investigation of their susceptibility to lytic bacteriophages. Antimicrob Agents Chemother. 2012;56(12):6175–80.
16. Semler DD, Goudie AD, Finlay WH, Dennis JJ. Aerosol phage therapy efficacy in Burkholderia cepacia Complex respiratory infections. Antimicrob Agents Chemother. 2014;58(7):4005–13.
17. Morello E, Saussereau E, Maura D, Huerre M, Touqui L, Debarbieux L. Pulmonary bacteriophage therapy on Pseudomonas aeruginosa cystic fibrosis strains: first steps towards treatment and prevention. Plos One. 2011;6(2), e16963.
18. Alemayehu D, Casey PG, McAuliffe O, Guinane CM, Martin JG, Shanahan F, et al. Bacteriophages phi MR299-2 and phi NH-4 can eliminate Pseudomonas aeruginosa in the murine lung and on cystic fibrosis lung airway cells. Mbio. 2012;3(2), e00029.
19. Wright A, Hawkins CH, Anggard EE, Harper DR. A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistant Pseudomonas aeruginosa; a preliminary report of efficacy, in Clin Otolaryngol. 2009;349–357.
20. Khawaldeh A, Morales S, Dillon B, Alavidze Z, Ginn AN, Thomas L, et al. Bacteriophage therapy for refractory Pseudomonas aeruginosa urinary tract infection. J Med Microbiol. 2011;60(11):1697–700.
21. Kutter E, Borysowski J, Miedzybrodzki R, Gorski A, Weber-Dabrowska B, Kutateladze M, et al. Clinical phage therapy. In: Borysowski J, Miedzybrodzki R, Gorski A, editors. Therapy: current research and applications. Caister Academic Press; 2014. p. 257–88.
22. Keen EC, Adhya SL. Phage therapy: current research and applications. Clin Infect Dis Off Publ Infect Dis Soc Am. 2015;61(1):141–2.
23. Kutateladze M, Adamia R. Bacteriophages as potential new therapeutics to replace or supplement antibiotics. Trends Biotechnol. 2010;28(12):591–5.
24. Semler DD, Lyunch KH, Dennis JJ. The promise of bacteriophage therapy for Burkholderia cepacia complex respiratory infections. Frontiers in cellular and infection microbiology, 2012. 1. UNSP 27.
25. Ackermann HW. 5500 phages examined in the electron microscope. Arch Virol. 2007;152(2):227–43.
26. Carmody LA, Gill JJ, Summer EJ, Sajjan US, Gonzalez CF, Young RF, et al. Efficacy of bacteriophage therapy in a model of Burkholderia cenocepacia pulmonary infection. J Infect Dis. 2010;201(2):264–71.
27. Golshahi L, Seed KD, Dennis JJ, Finlay WH. Toward modern inhalational bacteriophage therapy: nebulization of bacteriophages of Burkholderia cepacia Complex. J Aerosol Med Pulm Drug Deliv. 2008;21(4):351–9.
28. Sahota JS, Smith CM, Radhakrishnan P, Winstanley C, Goderdzishvili M, Chanishvili N, et al. Bacteriophage delivery by nebulization and efficacy against phenotypically diverse Pseudomonas aeruginosa from cystic fibrosis patients. J Aerosol Med Pulm Drug Deliv. 2015;28(5):353–60.
29. Golshahi L, Lynch KH, Dennis JJ, Finlay WH. In vitro lung delivery of bacteriophages KS4-M and Theta KZ using dry powder inhalers for treatment of Burkholderia cepacia complex and Pseudomonas aeruginosa infections in cystic fibrosis. J Appl Microbiol. 2011;110(1):106–17.
30. Matinkhoo S, Lynch KH, Dennis JJ, Finlay WH, Vehring R. Spray-dried respirable powders containing bacteriophages for the treatment of pulmonary infections. J Pharm Sci. 2011;100(12):5197–205.
31. Vandenheuvel D, Singh A, Vandersteegen K, Klumpp J, Lavigne R, Van den Mooter G. Feasibility of spray drying bacteriophages into respirable powders to combat pulmonary bacterial infections. Eur J Pharm Biopharm. 2013;84(3):578–82.
32. Vandenheuvel D, Meeus J, Lavigne R, Van den Mooter G. Instability of bacteriophages in spray-dried trehalose powders is caused by crystallization of the matrix. Int J Pharm. 2014;472(1–2):202–5.
33. Merabishvili M, Vervaet C, Pirnay J-P, De Vos D, Verbeken G, Mast J, et al. Stability of Staphylococcus aureus phage ISP after freeze-drying (Lyophilization). Plos One. 2013;8(7).
34. Ackermann HW, Tremblay D, Moineau S. Long-term bacteriophage preservation. World Fed Cult Collect Newsl. 2004;38:35–40.
35. Jepson CD, March JB. Bacteriophage lambda is a highly stable DNA vaccine delivery vehicle. Vaccine. 2004;22(19):2413–9.
36. D’Addio SM, Chan JGY, Kwok PCL, Benson BR, Prud’homme RK, Chan H-K. Aerosol delivery of nanoparticles in uniform mannitol carriers formulated by ultrasonic spray freeze drying. Pharm Res. 2013;30(11):2891–901.
37. Ceyssens P-J, Brabban A, Rogge L, Lewis MS, Pickard D, Goulding D, et al. Molecular and physiological analysis of three Pseudomonas aeruginosa phages belonging to the “N4-like viruses”. Virology. 2010;405(1):26–30.
38. Carlson K. Appendix. Working with bacteriophages: common techniques and methodological approaches. In: Kutter E, and Sulakvelidze A, editors. Bacteriophages: biology and applications. Boca Raton: CRC Press; 2005. p. 437–94.
39. Chopin MC. Resistance of 17 mesophilic lactic streptococcus bacteriophages to pasteurization and spray-drying. J Dairy Res. 1980;47(1):131–9.
40. Dixit N, Maloney KM, Kalonia DS. Protein-silicone oil interactions: comparative effect of nonionic surfactants on the interfacial behavior of a fusion protein. Pharm Res. 2013;30(7):1848–59.
41. Wang W. Lyophilization and development of solid protein pharmaceuticals. Int J Pharm. 2000;203(1–2):1–60.
42. Leuenberger H. Process of drying a particulate material and apparatus for implementing the process. 1987. US patent 4,608,764.
43. Wang ZL, Finlay WH, Peppler MS, Sweeney LG. Powder formation by atmospheric spray-freeze-drying. Powder Technol. 2006;170(1):45–52.
44. Sonner C, Maa YF, Lee G. Spray-freeze-drying for protein powder preparation: particle characterization and a case study with trypsinogen stability. J Pharm Sci. 2002;91(10):2122–39.
45. Feng AL, Boraey MA, Gwin MA, Finlay PR, Kuehl PJ, Vehring R. Mechanistic models facilitate efficient development of leucine containing microparticles for pulmonary drug delivery. Int J Pharm. 2011;409(1–2):156–63.
46. Surana R, Pyne A, Suryanarayanan R. Effect of preparation method on physical properties of amorphous trehalose. Pharm Res. 2004;21(7):1167–76.
47. Burnett DJ, Thielmann F, Booth J. Determining the critical relative humidity for moisture-induced phase transitions. Int J Pharm. 2004;287(1–2):123–33.
48. Kim AI, Akers MJ, Nail SL. The physical state of mannitol after freeze-drying: effects of mannitol concentration, freezing rate, and a noncrystallizing cosolute. J Pharm Sci. 1998;87(8):931–5.
49. Chen T, Bhowmick S, Sputtek A, Fowler A, Toner M. The glass transition temperature of mixtures of trehalose and hydroxyethyl starch. Cryobiology. 2002;44(3):301–6.
50. Burger A, Henck JO, Hetz S, Rollinger JM, Weissnicht AA, Stottner H. Energy/temperature diagram and compression behavior of the polymorphs of D-mannitol. J Pharm Sci. 2000;89(4):457–68.
51. Lahde A, Raula J, Malm J, Kauppinen EI, Karppinen M. Sublimation and vapour pressure estimation of L-leucine using thermogravimetric analysis. Thermochim Acta. 2009;482(1–2):17–20.
52. Vehring R. Pharmaceutical particle engineering via spray drying. Pharm Res. 2008;25(5):999–1022.
53. Maury M, Murphy K, Kumar S, Mauerer A, Lee G. Spray-drying of proteins: effects of sorbitol and trehalose on aggregation and FT-IR amide I spectrum of an immunoglobulin G. Eur J Pharm Biopharm. 2005;59(2):251–61.
54. Maa YF, Costantino HR, Nguyen PA, Hsu CC. The effect of operating and formulation variables on the morphology of spray-dried protein particles. Pharm Dev Technol. 1997;2(3):213–23.
55. Soothill JS. Treatment of experimental infections of mice with bacteriophages. J Med Microbiol. 1992;37(4):258–61.
56. Payne RJH, Jansen VAA. Pharmacokinetic principles of bacteriophage therapy. Clin Pharmacokinet. 2003;42(4):315–25.
57. Abedon ST. Phage therapy pharmacology: calculating phage dosing. Adv Appl Microbiol. 2011;77:1–40.
58. Curtright AJ, Abedon ST. Phage therapy: emergent property pharmacology. J Bioanal Biomed. 2011; S6, article 002.